The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

Drug Design, Development and Therapy - Tập Volume 12 - Trang 981-986
Yayi He1, Sangtian Liu1, Juan Lopez Mattei2, Paul A. Bunn3, Caicun Zhou1, Daniel C. Chan3
1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China
2Oncology Department, Moinhos de Vento Hospital, Porto Alegre, Brazil.
3Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Drug Design, Development and Therapy

Tập Volume 12

981-986

Thông tin tác giả